NoticiasCon ayuda de IA

Charles River Unveils Apollo™ for CRADL®: Accelerating Drug Discovery

Apollo™ simplifies research with seamless tools, boosting efficiency in drug discovery programs.

Mrudula Kulkarni
Por Mrudula Kulkarni
Editor Gerente - Pharma Now
22 ene 2025Updated Jun 26, 2025 · 2 min de lectura
Charles River Unveils Apollo™ for CRADL®: Accelerating Drug Discovery
https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.criver.com%2Fproducts-services%2Fdiscovery-services%2Fdiscovery-facilities&psig=AOvVaw0D41pz9401L-2grCqRcDHC&ust=1737622618540000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCID_oez6iIsDFQAAAAAdAAAAABAE
Reportaje con ayuda de IA
Reviewed by Mrudula Kulkarni, Editor Gerente - Pharma Now

Charles River Laboratories International, Inc. has introduced Apollo™ for CRADL®, a secure, cloud-based platform that revolutionizes vivarium rental services by streamlining research processes. Designed to support clients launching or expanding drug discovery programs, Apollo simplifies onboarding and integrates seamlessly with Charles River’s Research Models Online Ordering System, training tools, and other services. This centralized platform provides direct control over reservations, protocol management, and research execution, enabling faster and more efficient project initiation.

Mark Mintz, Corporate Senior Vice President and CIO of Charles River, emphasized Apollo's role in driving the company's digital transformation, offering clients access to real-time data and tools that optimize research processes. With applications extending across safety assessment, biologics, oncology studies, and more, Apollo represents a comprehensive innovation aimed at accelerating drug discovery and development. By reducing administrative hurdles and enhancing operational efficiency, Charles River continues to lead in delivering cutting-edge solutions for the scientific community.

Mrudula Kulkarni
Written by
Mrudula Kulkarni
Editor Gerente - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Cargando la conversación…

Más de Pharma News

Todos los artículos →